Hugely positive Phase III top-line data for Shire PLC’s monoclonal antibody product lanadelumab in acute HAE represents "an historic event" for the rare disease specialist, vindicates its purchase of Dyax Corp. in late 2015, and keeps the asset on track for eventual "blockbuster" status, CEO Flemming Ornskov told Scrip in an interview.
He was commenting after the world's biggest rare disease specialist announced that its Phase III HELP trial, evaluating lanadelumab (or SHP643), a long-acting therapy for hereditary angioedema, met all primary and
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?